WO1997044474A3 - Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire - Google Patents

Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire Download PDF

Info

Publication number
WO1997044474A3
WO1997044474A3 PCT/FR1997/000870 FR9700870W WO9744474A3 WO 1997044474 A3 WO1997044474 A3 WO 1997044474A3 FR 9700870 W FR9700870 W FR 9700870W WO 9744474 A3 WO9744474 A3 WO 9744474A3
Authority
WO
WIPO (PCT)
Prior art keywords
terminal
receptor
peptide
protein domain
upstream
Prior art date
Application number
PCT/FR1997/000870
Other languages
English (en)
Other versions
WO1997044474A2 (fr
Inventor
Francois-Loic Cosset
Sandrine Valsesia
Stephen J Russell
Original Assignee
Centre Nat Rech Scient
Cosset Francois Loic
Sandrine Valsesia
Stephen J Russell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Cosset Francois Loic, Sandrine Valsesia, Stephen J Russell filed Critical Centre Nat Rech Scient
Priority to EP97925095A priority Critical patent/EP0953053A2/fr
Priority to AU30356/97A priority patent/AU725632B2/en
Priority to CA002253874A priority patent/CA2253874A1/fr
Priority to JP09541705A priority patent/JP2000511051A/ja
Publication of WO1997044474A2 publication Critical patent/WO1997044474A2/fr
Publication of WO1997044474A3 publication Critical patent/WO1997044474A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/852—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from cytokines; from lymphokines; from interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'un peptide en vue d'un transfert de gènes dans une cellule eucaryote cible, lequel peptide présente d'environ 10 à environ 200, notamment d'environ 15 à environ 150 acides aminés, et avantageusement environ 20 acides aminés, dans lequel 30 % au moins des acides aminés sont constitués par des résidus proline, lesquels résidus proline sont régulièrement agencés de manière à induire des repliements de la chaîne polypeptidique à environ 180° ('β-turn' ou 'reverse-turn'), ces repliements étant régulièrement espacés et s'assemblant en une hélice polyproline à repliement de type β ('polyproline β-turn helix'), dans une construction polypeptidique contenant, du côté N-terminal (en amont) dudit peptide, un domaine protéique N-terminal (amont) susceptible de reconnaître une molécule de surface ciblée ou un antigène exprimé sur une surface cellulaire, notamment un récepteur approprié (récepteur ciblé) situé sur ladite cellule eucaryote, et du côté C-terminal (en aval) dudit peptide, un domaine protéique C-terminal (aval) susceptible de reconnaître un récepteur approprié (récepteur auxiliaire) situé sur la susdite cellule eucaryote, lequel peptide est capable de faciliter ou d'inhiber l'interaction entre le domaine protéique C-terminal (aval) et le récepteur auxiliaire, l'inhibition de cette interaction ayant lieu tant que le domaine protéique N-terminal (amont) n'a pas interagi avec le récepteur ciblé et la favorisation de l'interaction entre le domaine protéique C-terminal (aval) et le récepteur auxiliaire ayant lieu lorsque le domaine protéique N-terminal (amont) a interagi avec le récepteur ciblé.
PCT/FR1997/000870 1996-05-20 1997-05-16 Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire WO1997044474A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97925095A EP0953053A2 (fr) 1996-05-20 1997-05-16 Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire
AU30356/97A AU725632B2 (en) 1996-05-20 1997-05-16 Viral particles which are masked or unmasked with respect to a cell receptor
CA002253874A CA2253874A1 (fr) 1996-05-20 1997-05-16 Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire
JP09541705A JP2000511051A (ja) 1996-05-20 1997-05-16 細胞受容体に関してマスキングされているか又は非マスキング（ｕｎｍａｓｋｅｄ）されたウイルス粒子

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9606234A FR2748747B1 (fr) 1996-05-20 1996-05-20 Particules virales recombinantes comportant un peptide ayant des proprietes de masquage et de demasquage vis-a-vis d'un mecanisme biologique
FR96/06234 1996-05-20

Publications (2)

Publication Number Publication Date
WO1997044474A2 WO1997044474A2 (fr) 1997-11-27
WO1997044474A3 true WO1997044474A3 (fr) 1998-03-05

Family

ID=9492280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1997/000870 WO1997044474A2 (fr) 1996-05-20 1997-05-16 Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire

Country Status (6)

Country Link
EP (1) EP0953053A2 (fr)
JP (1) JP2000511051A (fr)
AU (1) AU725632B2 (fr)
CA (1) CA2253874A1 (fr)
FR (1) FR2748747B1 (fr)
WO (1) WO1997044474A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773561A1 (fr) * 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
WO2000071578A2 (fr) * 1999-05-20 2000-11-30 Cnrs Centre National De La Recherche Scientifique Nouveaux polypeptides et leur utilisation pour le sauvetage de virus ou de glycoproteines virales a defaut de fusion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010099A1 (fr) * 1988-04-21 1989-11-02 Uab Research Foundation Materiaux bioelastomeres adaptes pour empecher que des adherences ne se produisent sur des sites de reparation de blessure
WO1994011524A1 (fr) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Particules vectorielles pouvant etre ciblees
EP0610046A2 (fr) * 1993-02-01 1994-08-10 Bristol-Myers Squibb Company Vecteurs d'expression codant pour des proteins de fusion bispécifiques et méthodes pour la production de ces protéins dans des cellules de mammifèrres
WO1995023611A1 (fr) * 1994-03-03 1995-09-08 Protein Polymer Technologies, Inc. Produits comprenant des substrats capables de reticulation enzymatique
WO1996000294A1 (fr) * 1994-06-27 1996-01-04 Medical Research Council Ameliorations relatives a l'apport d'acides nucleiques
WO1996003427A1 (fr) * 1994-07-22 1996-02-08 Resolution Pharmaceuticals Inc. Chelateurs a radionucleides, derives de peptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010099A1 (fr) * 1988-04-21 1989-11-02 Uab Research Foundation Materiaux bioelastomeres adaptes pour empecher que des adherences ne se produisent sur des sites de reparation de blessure
WO1994011524A1 (fr) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Particules vectorielles pouvant etre ciblees
EP0610046A2 (fr) * 1993-02-01 1994-08-10 Bristol-Myers Squibb Company Vecteurs d'expression codant pour des proteins de fusion bispécifiques et méthodes pour la production de ces protéins dans des cellules de mammifèrres
WO1995023611A1 (fr) * 1994-03-03 1995-09-08 Protein Polymer Technologies, Inc. Produits comprenant des substrats capables de reticulation enzymatique
WO1996000294A1 (fr) * 1994-06-27 1996-01-04 Medical Research Council Ameliorations relatives a l'apport d'acides nucleiques
WO1996003427A1 (fr) * 1994-07-22 1996-02-08 Resolution Pharmaceuticals Inc. Chelateurs a radionucleides, derives de peptides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COSSET F -L ET AL: "RETROVIRAL RETARGETING BY ENVELOPES EXPRESSING AN N-TERMINAL LIGAND", CANCER GENE THERAPY, vol. 2, no. 3, September 1995 (1995-09-01), pages 237, XP000613600 *
NILSON B H K ET AL: "TWO-STEP TARGETING OF RETROVIRAL VECTORS", JOURNAL OF MOLECULAR MEDICINE, vol. 74, no. 4, 18 April 1996 (1996-04-18), pages B09, XP000613835 *
NUSSBAUM, O. ET AL.: "Sequences determinig the pH dependence of viral entry are distinct from the host range-determining region of the murine ecotropic and amphotropic retrovirus envelope proteins", JOURNAL OF VIROLOGY., vol. 67, no. 12, December 1993 (1993-12-01), ICAN SOCIETY FOR MICROBIOLOGY US, pages 7402 - 7405, XP002045867 *
OTT, D. ET AL.: "Sequence analysis of amphotropic and 10A1 Murine Leukemia viruses: close relationship to Mink Cell Focus-inducing viruses", JOURNAL OF VIROLOGY., vol. 64, no. 2, February 1990 (1990-02-01), ICAN SOCIETY FOR MICROBIOLOGY US, pages 757 - 766, XP002045868 *
VALSESIA-WITTMANN S ET AL: "IMPROVEMENT OF RETROVIRAL RETARGETING BY USING AMINO ACID SPACERS BETWEEN AN ADDITIONAL BINDING DOMAIN AND THE N TERMINUS OF MOLONEY MURINE LEUKEMIA VIRUS SU", JOURNAL OF VIROLOGY, vol. 70, no. 3, March 1996 (1996-03-01), pages 2059 - 2064, XP000613624 *
VALSESIA-WITTMANN S ET AL: "IMPROVEMENT OF RETROVIRAL RETARGETING USING AMINO-ACIDS SPACERS BETWEEN AN ADDITIONAL BINDING DOMAIN AND THE N-TERMINUS OF MOMLV SU", GENE THERAPY, vol. 2, no. SUPPL. 01, 17 November 1995 (1995-11-17), pages S14, XP000613591 *
VALSESIA-WITTMANN, S. ET AL.: "Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding", EMBO JOURNAL., vol. 16, 1997, EYNSHAM, OXFORD GB, pages 1214 - 1213, XP002045869 *

Also Published As

Publication number Publication date
WO1997044474A2 (fr) 1997-11-27
AU3035697A (en) 1997-12-09
AU725632B2 (en) 2000-10-19
CA2253874A1 (fr) 1997-11-27
EP0953053A2 (fr) 1999-11-03
FR2748747B1 (fr) 1998-08-07
FR2748747A1 (fr) 1997-11-21
JP2000511051A (ja) 2000-08-29

Similar Documents

Publication Publication Date Title
NZ336929A (en) Purified receptor that binds TRAIL and antibodies thereof
ATE257160T1 (de) Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde
WO2005051998A3 (fr) Anticorps
WO1999058571A3 (fr) Proteine hybride pour l'inhibition de la degranulation des mastocytes et son utilisation
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
WO2002092771A3 (fr) Proteines de liaison specifiques et utilisations associees
Geschwind et al. The Structure of the β-Melanocyte-stimulating Hormone
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
WO2000032631A3 (fr) Compositions et procedes d'utilisation de proteines et de peptides fixant des proteines inhibant l'angiogenese
EP1939293A3 (fr) Protéine ZCYTO21 d'interféron
WO2002016418A3 (fr) Peptide ou polypeptide capable de liaison avec l'inhibiteur de la proteine de l'apoptose
ATE488249T1 (de) Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
WO2007029262A3 (fr) Compositions et methodes d'utilisation de ces dernieres en vue de detecter des virus
EA201001190A1 (ru) Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
WO1999063086A3 (fr) Variantes de la proteine-3 de liaison du facteur de croissance de type insulinoide
WO1997044474A3 (fr) Particules virales masquees ou demasquees vis-a-vis du recepteur cellulaire
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
FI964363A0 (fi) Peptidejä
AUPP627498A0 (en) Novel peptides - i
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
WO2008012689A3 (fr) Dérivés citokine
AU2865801A (en) Therapeutic peptides
AU6310100A (en) Single-chain polypeptides comprising troponin i n-terminal fragments and troponin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2253874

Country of ref document: CA

Ref country code: CA

Ref document number: 2253874

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997925095

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997925095

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997925095

Country of ref document: EP